Geron (GERN) Interest & Investment Income (2010 - 2026)
Geron (GERN) posted Interest & Investment Income of $3.4 million for Q1 2026, down 15.43% sequentially from $4.0 million in Q4 2025, and down 33.6% YoY from $5.2 million in Q1 2025.
Geron (GERN) Interest & Investment Income (2010 - 2026) Analysis & Trends
Geron has reported Interest & Investment Income for 17 years, with the latest figure at $3.4 million in Q1 2026.
- Quarterly Interest & Investment Income fell 33.6% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.4 million (down 20.15% YoY) and the FY2025 annual result came in at $18.1 million, down 7.6% from the prior year.
- Interest & Investment Income eased to $3.4 million in Q1 2026 per GERN's latest filing, from $4.0 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $5.3 million in Q2 2024 and troughed at -$539000.0 in Q1 2022.
- A 5-year average of $3.6 million and a median of $4.3 million in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income tumbled 411.56% in 2022, then surged 1335.76% in 2023.
- Over 5 years, Interest & Investment Income stood at $1.2 million in 2022, then jumped by 272.15% to $4.6 million in 2023, then climbed by 12.25% to $5.2 million in 2024, then declined by 21.59% to $4.0 million in 2025, then slipped by 15.43% to $3.4 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $3.4 million, $4.0 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 2.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.97 Mn |
| Mar 31, 2026 | 3.42 Mn |
| Dec 31, 2025 | 4.05 Mn |
| Sep 30, 2025 | 4.26 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Mar 31, 2025 | 5.15 Mn |
| Dec 31, 2024 | 5.16 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Jun 30, 2024 | 5.33 Mn |
| Mar 31, 2024 | 4.24 Mn |
| Dec 31, 2023 | 4.60 Mn |
| Sep 30, 2023 | 4.97 Mn |
| Jun 30, 2023 | 4.74 Mn |
| Mar 31, 2023 | 3.85 Mn |
| Dec 31, 2022 | 1.24 Mn |
| Sep 30, 2022 | 852,000.00 |
| Jun 30, 2022 | 330,000.00 |
| Mar 31, 2022 | -539,000.00 |
| Dec 31, 2021 | 106,000.00 |
| Sep 30, 2021 | 112,000.00 |